Table 1.

Baseline demographic characteristics (safety population)

ParameterNondialysis StudyHDD Study
Placebo (n=18)GSK1278863Total (n=72)rhEPO (n=20)GSK1278863Total (n=82)
0.5 mg (n=17)2 mg (n=18)5 mg (n=19)0.5 mg (n=21)2 mg (n=21)5 mg (n=20)
Age (yr)69.2±11.066.6±11.766.9±11.471.3±11.368.6±11.364.2±12.856.4±16.855.2±18.455.6±17.957.8±16.8
Women14 (78)12 (71)10 (56)16 (84)52 (72)4 (20)3 (14)8 (38)8 (40)23 (28)
Race
n19161818712021201980
 White12 (63)10 (63)12 (67)14 (78)48 (68)14 (70)14 (67)14 (70)12 (63)54 (68)
 African American4 (21)4 (25)4 (22)2 (11)14 (20)4 (20)7 (33)3 (15)4 (21)18 (23)
 Asian2 (11)2 (13)2 (11)1 (6)7 (10)003 (15)2 (11)5 (6)
 Other1 (5)001 (6)2 (3)2 (10)001 (5)3 (4)
BMI (kg/m2)32.1 (9.6)34.2 (9.7)30.6 (5.5)31.2 (7.6)32.0 (8.2)29.4±7.728.7±8.129.4±5.930.3±9.429.5±7.7
Baseline eGFR (ml/min per 1.73 m2)a23.2±11.523.8±9.824.2±12.524.2±10.823.8±11.0
CKD stagea
 3a1 (6)1 (6)2 (11)1 (5)5 (7)
 3b3 (17)4 (24)3 (17)5 (26)15 (21)
 48 (44)9 (53)7 (39)8 (42)32 (44)
 56 (33)3 (18)6 (33)5 (26)20 (28)
Cardiovascular risk factors
 Any condition18 (100)17 (100)18 (100)19 (100)72 (100)20 (100)20 (95)19 (90)19 (95)78 (95)
 Angina pectoris1 (6)1 (6)3 (17)1 (5)6 (8)6 (30)2 (10)3 (14)2 (10)13 (16)
 Diabetes12 (67)12 (71)14 (78)12 (63)50 (69)11 (55)8 (38)10 (48)8 (40)37 (45)
 Hyperlipidemia14 (78)11 (65)13 (72)17 (89)55 (76)14 (70)11 (52)11 (52)11 (55)47 (57)
 Hypertension17 (94)16 (94)18 (100)19 (100)70 (97)20 (100)20 (95)19 (90)19 (95)78 (95)
 MI01 (6)3 (17)1 (5)5 (7)6 (30)1 (5)3 (14)010 (12)
 Stroke001 (6)1 (5)2 (3)1 (5)1 (5)2 (10)1 (5)5 (6)
  • Unless otherwise indicated, all values are given as means±SD or n (%). BMI, body mass index; MI, myocardial infarction.

  • a Not applicable for the HDD study.